A leadership team making a difference by going the extra mile

Scott’s leadership experience is unparalleled, with more than 25 years of leading highly successful teams at some of the biggest pharmaceutical companies across multiple therapeutic areas. He has experience in oncology, immunology, neuroscience, rare diseases, targeted therapies, and specialty pharmaceuticals. He’s held a broad range of roles—including sales, marketing, operations, access, patient services, and managing director—giving him vast knowledge of the industry. He previously served as Chief Commercial Officer at Merck KGaA, EMD Serono where his teams successfully launched multiple new medicines.

Jeff’s strategic mindset and authentic leadership style make him well suited for his role in leading commercial strategy and global operations at Luzsana. He has more than 25 years of healthcare leadership experience in marketing, sales, market access, patient services, business development, and investor relations. Most recently Jeff was at SK Life Science, a relatively unknown South Korean biopharmaceutical company where he played a foundational role in building the company’s commercial organization. Under Jeff’s leadership, SK successfully launched XCOPRI^® in the US epilepsy marketplace during a global pandemic, marking the first time a Korea-based company discovered and commercialized a molecule from inception through FDA approval without partnering or out-licensing. Jeff is a proven strategic builder uniquely qualified to lead Luzsana’s commercial and global operations functions at this stage of our company’s development.

Joe attended medical school during the height of the Lebanon civil war, and although it was dangerous, he was determined to complete his studies.

After medical school, he completed a residency in internal medicine and a fellowship in hematology and oncology. He then began practicing medicine in the United States, where he held an unwavering commitment to putting patients first. When he moved from academic medicine to the pharmaceutical industry, he brought that mindset with him, which helped him successfully lead clinical development and medical affairs departments at Roche, Merck, and BMS.

Today, Dr Eid, who is board-certified in medical oncology, hematology, and internal medicine, is responsible for developing and managing early- and late-stage product development across all therapeutic areas at Luzsana.

He has more than 25 years of experience in academic medicine and in the biopharmaceutical industry. He has led major programs across all phases of development, including small molecules, monoclonal antibodies, and immuno-oncology.

Joe is a highly accomplished financial executive, with 20 years of experience in the pharmaceutical industry. His vast senior-level experience in building and managing global finance teams is poised to help grow and prepare Luzsana for an exciting future.

He’s worked at a broad range of biopharma companies including Celularity, MYOS, Allergan, and Celgene, where he had experience in global public accounting and reporting, budgeting and forecasting, business acquisitions and collaborations, strategic planning, and capital-raising initiatives.

Leah is a human resources executive with a diverse background working for a broad range of pharmaceutical companies, from large global companies to small biotechs. She has worked in multiple areas of the pharmaceutical world including rare and orphan biotech, gene therapy, R&D centers, device, consumer, supply chain, manufacturing, and technical operations.

Yi is a results-driven life sciences and healthcare executive with a track record of delivering high-quality and impactful solutions. She is equipped with more than 20 years of industry (Merck, Novartis) and consulting (Deloitte) experience in biopharma, medical devices, and adjacent sectors in multiple functional settings (R&D, commercial, supply chain, compliance, IT, finance), product segments, and therapeutic areas. Yi is recognized as an effective problem solver, practical strategist, and efficient executer.